NK cells and interferons

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 113-120

  Paolini, Rossella ^a   Bernardini, Giovanni ^a   Molfetta, Rosa ^a   Santoni, Angela ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Antiviral response; Cytotoxicity; Interferon ; NK cells; Type I interferon

Indexed keywords

GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12; STAT1 PROTEIN; STAT4 PROTEIN; CHEMOKINE; CYTOKINE; INTERLEUKIN 15;

ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL PROTECTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNOPATHOLOGY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; CHEMOKINES; CYTOKINES; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; STAT1 TRANSCRIPTION FACTOR; STAT4 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 84926451174     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.11.003     Document Type: Article

References (108)

1. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
2. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
3. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999, 17:189-220.
4. Raulet D.H., Vance R.E., McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001, 19:291-330.
5. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
6. Raulet D.H., Gasser S., Gowen B.G., Deng W., Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013, 31:413-441.
7. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
8. Soriani A., Zingoni A., Cerboni C., Iannitto M.L., Ricciardi M.R., Di Gialleonardo V., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113:3503-3511.
9. McQueen K.L., Parham P. Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol 2002, 14:615-621.
10. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202:8-32.
11. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
12. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978, 147:1314-1333.
13. Welsh R.M., Zinkernagel R.M. Heterospecific cytotoxic cell activity induced during the first three days of acute lymphocytic choriomeningitis virus infection in mice. Nature 1977, 268:646-648.
14. Gidlund M., Orn A., Wigzell H., Senik A., Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978, 273:759-761.
15. Oehler J.R., Lindsay L.R., Nunn M.E., Holden H.T., Herberman R.B. Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity. Int J Cancer 1978, 21:210-220.
16. Herberman R.B., Djeu J.Y., Ortaldo J.R., Holden H.T., West W.H., Bonnard G.D. Role of interferon in augmentation of natural and antibody-dependent cell-mediated cytotoxicity. Cancer Treat Rep 1978, 62:1893-1896.
17. Orange J.S., Biron C.A. Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol 1996, 156:4746-4756.
18. Nguyen K.B., Salazar-Mather T.P., Dalod M.Y., Van Deusen J.B., Wei X.Q., Liew F.Y., et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 2002, 169:4279-4287.
19. Sato K., Hida S., Takayanagi H., Yokochi T., Kayagaki N., Takeda K., et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001, 31:3138-3146.
20. Miyagi T., Takehara T., Nishio K., Shimizu S., Kohga K., Li W., et al. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010, 53:424-430.
21. Swann J.B., Hayakawa Y., Zerafa N., Sheehan K.C., Scott B., Schreiber R.D., et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007, 178:7540-7549.
22. Perussia B., Fanning V., Trinchieri G. A leukocyte subset bearing HLA-DR antigens is responsible for in vitro alpha interferon production in response to viruses. Nat Immun Cell Growth Regul 1985, 4:120-137.
23. Fitzgerald-Bocarsly P. Human natural interferon-alpha producing cells. Pharmacol Ther 1993, 60:39-62.
24. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
25. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999, 5:919-923.
26. Asselin-Paturel C., Boonstra A., Dalod M., Durand I., Yessaad N., Dezutter-Dambuyant C., et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001, 2:1144-1150.
27. Nakano H., Yanagita M., Gunn M.D. CD11c+B220+Gr-1+ cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001, 194:1171-1178.
28. Fernandez N.C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999, 5:405-411.
29. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002, 195:327-333.
30. Degli-Esposti M.A., Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005, 5:112-124.
31. Jinushi M., Takehara T., Kanto T., Tatsumi T., Groh V., Spies T., et al. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 2003, 170:1249-1256.
32. Martinez J., Huang X., Yang Y. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J Immunol 2008, 180:1592-1597.
33. Zhu J., Huang X., Yang Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol Ther 2008, 16:1300-1307.
34. Mack E.A., Kallal L.E., Demers D.A., Biron C.A. Type 1 interferon induction of natural killer cell gamma interferon production for defense during lymphocytic choriomeningitis virus infection. MBio 2011, 2. pii: e00169-11.
35. Lucas M., Schachterle W., Oberle K., Aichele P., Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517.
36. Beuneu H., Deguine J., Bouvier I., Di Santo J.P., Albert M.L., Bousso P. Cutting edge: a dual role for type I IFNs during polyinosinic-polycytidylic acid-induced NK cell activation. J Immunol 2011, 187:2084-2088.
37. Baranek T., Manh T.P., Alexandre Y., Maqbool M.A., Cabeza J.Z., Tomasello E., et al. Differential responses of immune cells to type I interferon contribute to host resistance to viral infection. Cell Host Microbe 2012, 12:571-584.
38. Zanoni I., Spreafico R., Bodio C., Di Gioia M., Cigni C., Broggi A., et al. IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Rep 2013, 4:1235-1249.
39. Biron C.A., Sonnenfeld G., Welsh R.M. Interferon induces natural killer cell blastogenesis in vivo. J Leukoc Biol 1984, 35:31-37.
40. Santoni A., Piccoli M., Ortaldo J.R., Mason L., Wiltrout R.H., Herberman R.B. Changes in number and density of large granular lymphocytes upon in vivo augmentation of mouse natural killer activity. J Immunol 1985, 134:2799-2810.
41. Jewett A., Bonavida B. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol 1995, 15:35-44.
42. Nguyen K.B., Cousens L.P., Doughty L.A., Pien G.C., Durbin J.E., Biron C.A. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000, 1:70-76.
43. Car B.D., Eng V.M., Schnyder B., Ozmen L., Huang S., Gallay P., et al. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med 1994, 179:1437-1444.
44. Nguyen K.B., Watford W.T., Salomon R., Hofmann S.R., Pien G.C., Morinobu A., et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002, 297:2063-2066.
45. Miyagi T., Gil M.P., Wang X., Louten J., Chu W.M., Biron C.A. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med 2007, 204:2383-2396.
46. Edlich B., Ahlenstiel G., Zabaleta Azpiroz A., Stoltzfus J., Noureddin M., Serti E., et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012, 55:39-48.
47. Ahlenstiel G., Titerence R.H., Koh C., Edlich B., Feld J.J., Rotman Y., et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010, 138:325-335.
48. Lanier L.L. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008, 8:259-268.
49. Lisnić V.J., Krmpotić A., Jonjić S. Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 2010, 13:530-539.
50. Lee S.H., Girard S., Macina D., Busà M., Zafer A., Belouchi A., et al. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 2001, 28:42-45.
51. Brown M.G., Dokun A.O., Heusel J.W., Smith H.R., Beckman D.L., Blattenberger E.A., et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 2001, 292:934-937.
52. Arase H., Mocarski E.S., Campbell A.E., Hill A.B., Lanier L.L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002, 296:1323-1326.
53. Smith H.R., Heusel J.W., Mehta I.K., Kim S., Dorner B.G., Naidenko O.V., et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA 2002, 99:8826-8831.
54. Dokun A.O., Kim S., Smith H.R., Kang H.S., Chu D.T., Yokoyama W.M. Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2001, 2:951-956.
55. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
56. Kielczewska A., Pyzik M., Sun T., Krmpotic A., Lodoen M.B., Munks M.W., et al. Ly49P recognition of cytomegalovirus-infected cells expressing H2-Dk and CMV-encoded m04 correlates with the NK cell antiviral response. J Exp Med 2009, 206:515-523.
57. Gumá M., Budt M., Sáez A., Brckalo T., Hengel H., Angulo A., et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 2006, 107:3624-3631.
58. Oliviero B., Varchetta S., Paudice E., Michelone G., Zaramella M., Mavilio D., et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009, 137:1151-1160.
59. Stewart C.A., Laugier-Anfossi F., Vély F., Saulquin X., Riedmuller J., Tisserant A., et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005, 102:13224-13229.
60. Jost S., Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol 2013, 31:163-194.
61. Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997, 7:273-282.
62. Tomasec P., Braud V.M., Rickards C., Powell M.B., McSharry B.P., Gadola S., et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000, 287:1031.
63. Nattermann J., Nischalke H.D., Hofmeister V., Ahlenstiel G., Zimmermann H., Leifeld L., et al. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005, 166:443-453.
64. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
65. Gazit R., Gruda R., Elboim M., Arnon T.I., Katz G., Achdout H., et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 2006, 7:517-523.
66. Rossini G., Cerboni C., Santoni A., Landini M.P., Landolfo S., Gatti D., et al. Interplay between human cytomegalovirus and intrinsic/innate host responses: a complex bidirectional relationship. Mediators Inflamm 2012, 2012:607276.
67. Cerboni C., Fionda C., Soriani A., Zingoni A., Doria M., Cippitelli M., et al. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front Immunol 2014, 4:508.
68. Groh V., Rhinehart R., Randolph-Habecker J., Topp M.S., Riddell S.R., Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001, 2:255-260.
69. Welte S.A., Sinzger C., Lutz S.Z., Singh-Jasuja H., Sampaio K.L., Eknigk U., et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 2003, 33:194-203.
70. Rölle A., Mousavi-Jazi M., Eriksson M., Odeberg J., Söderberg-Nauclér C., Cosman D., et al. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 2003, 171:902-908.
71. Tomasec P., Wang E.C., Davison A.J., Vojtesek B., Armstrong M., Griffin C., et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141 72. Nat Immunol 2005, 6:181-188.
72. Prod'homme V., Sugrue D.M., Stanton R.J., Nomoto A., Davies J., Rickards C.R., et al. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J Gen Virol 2010, 91:2034-2039.
73. Pappworth I.Y., Wang E.C., Rowe M. The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 2007, 81:474-482.
74. Cerboni C., Neri F., Casartelli N., Zingoni A., Cosman D., Rossi P., et al. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol 2007, 88:242-250.
75. Ward J., Bonaparte M., Sacks J., Guterman J., Fogli M., Mavilio D., et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 2007, 110:1207-1214.
76. Matusali G., Potestà M., Santoni A., Cerboni C., Doria M. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 2012, 86:4496-4504.
77. Sirén J., Sareneva T., Pirhonen J., Strengell M., Veckman V., Julkunen I., et al. Cytokine and contact-dependent activation of natural killer cells by influenza A or Sendai virus-infected macrophages. J Gen Virol 2004, 85:2357-2364.
78. Fang M., Lanier L.L., Sigal L.J. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog 2008, 4:e30.
79. Bukowski J.F., Woda B.A., Welsh R.M. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J Virol 1984, 52:119-128.
80. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989, 320:1731-1735.
81. Orange J.S. Natural killer cell deficiency. J Allergy Clin Immunol 2013, 132:515-525.
82. García-Sastre A. Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology 2001, 279:375-384.
83. Voskoboinik I., Smyth M.J., Trapani J.A. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006, 6:940-952.
84. Orange J.S., Wang B., Terhorst C., Biron C.A. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med 1995, 182:1045-1056.
85. Novelli F., Casanova J.L. The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev 2004, 15:367-377.
86. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001, 19:65-91.
87. Crotta S., Brazzoli M., Piccioli D., Valiante N.M., Wack A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol 2010, 52:183-190.
88. Kos F.J., Engleman E.G. Requirement for natural killer cells in the induction of cytotoxic T cells. J Immunol 1995, 155:578-584.
89. Martín-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004, 5:1260-1265.
90. Salazar-Mather T.P1, Hamilton T.A., Biron C.A. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. Clin Invest 2000, 105:985-993.
91. Gao N., Dang T., Yuan D. IFN-gamma-dependent and -independent initiation of switch recombination by NK cells. J Immunol 2001, 167:2011-2018.
92. Fairweather D., Kaya Z., Shellam G.R., Lawson C.M., Rose N.R. From infection to autoimmunity. J Autoimmun 2001, 16:175-186.
93. Robbins S.H., Bessou G., Cornillon A., Zucchini N., Rupp B., Ruzsics Z., et al. Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog 2007, 3:e123.
94. van Dommelen S.L., Sumaria N., Schreiber R.D., Scalzo A.A., Smyth M.J., Degli-Esposti M.A. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 2006, 25:835-848.
95. Lee S.H., Kim K.S., Fodil-Cornu N., Vidal S.M., Biron C.A. Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection. J Exp Med 2009, 206:2235-2251.
96. De Maria A., Fogli M., Mazza S., Basso M., Picciotto A., Costa P., et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007, 37:445-455.
97. Waggoner S.N., Cornberg M., Selin L.K., Welsh R.M. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2011, 481:394-398.
98. Welsh R.M., Waggoner S.N. NK cells controlling virus-specific T cells: rheostats for acute vs. persistent infections. Virology 2013, 435:37-45.
99. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013, 19:859-868.
100. Lang P.A., Lang K.S., Xu H.C., Grusdat M., Parish I.A., Recher M., et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci USA 2012, 109:1210-1215.
101. Xu H.C., Grusdat M., Pandyra A.A., Polz R., Huang J., Sharma P., et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 2014, 40:949-960.
102. Crouse J., Bedenikovic G., Wiesel M., Ibberson M., Xenarios I., Von Laer D., et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity 2014, 40:961-973.
103. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-874.
104. Knapp S., Warshow U., Hegazy D., Brackenbury L., Guha I.N., Fowell A., et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 2010, 51:1168-1175.
105. Wiesel M., Crouse J., Bedenikovic G., Sutherland A., Joller N., Oxenius A. Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. Eur J Immunol 2012, 42:320-329.
106. Cox M.A., Kahan S.M., Zajac A.J. Anti-viral CD8 T cells and the cytokines that they love. Virology 2013, 435:157-169.
107. Oliviero B., Mele D., Degasperi E., Aghemo A., Cremonesi E., Rumi M.G., et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol 2013, 59:38-44.
108. Li F., Zhu H., Sun R., Wei H., Tian Z. Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. J Virol 2012, 86:2251-2258.